Trial Profile
NEW-ONSET DIABETES MELLITUS AFTER RENAL TRANSPLANTATION. A MULTICENTRE, PROSPECTIVE, RANDOMIZED, OPEN STUDY TO EVALUATE BELATACEPT-BASED VERSUS TACROLIMUS-BASED IMMUNOSUPPRESSION
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 01 Aug 2022
Price :
$35
*
At a glance
- Drugs Belatacept (Primary) ; Immunosuppressants; Tacrolimus
- Indications Diabetes mellitus; Prediabetic state; Renal transplant rejection
- Focus Therapeutic Use
- Acronyms NODAT-BELATAC
- 30 Jul 2022 Status changed to discontinued.
- 21 Aug 2013 New trial record